Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53

Cancer Cell International
Fei ZhouXiaoming Yang

Abstract

Basal/human epidermal growth factor receptor (HER)2-positive (HER2+) breast cancer is resistant to monoclonal antibody (herceptin) treatment. There are currently only three basal/HER2+ breast cancer cell lines available, but they are not from Chinese populations. Three immortalized cell lines (ZJU-0327, ZJU-0725, and ZJU-1127) were established from invasive ductal breast carcinoma tissue of two patients treated by surgical resection at our center. The cell lines were characterized in terms of histology, therapeutic response, and biomarker expression. Their tumorigenic potential was evaluated in an athymic nude (BALB/C nu) mouse xenograft model. Cell authentication testing by the techniques of short tandem repeat. ZJU-0327, ZJU-0725, and ZJU-1127 cell lines were maintained for more than 110 passages in vitro. The cells grew as monolayers; showed typical epithelial morphology and ultrastructure; were polyploid; had doubling times of 18, 57.5, and 18 h, respectively; had a near-tetraploid (ZJU-0327 and ZJU-1127) or aneuploid (ZJU-0725) karyotype with structural aberrations and tumor protein 53 mutation; insensitive to chemotherapeutic drugs and/or radiation; show high invasiveness and tumorigenicity in mice; and had no mycoplasma ...Continue Reading

References

May 1, 1979·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I KeydarH J Brenner
Jan 1, 1987·Breast Cancer Research and Treatment·C K OsborneJ M Trent
Nov 1, 1973·Journal of the National Cancer Institute·H D SouleM Brennan
Aug 30, 2000·Nature·C M PerouD Botstein
Mar 13, 2003·Breast Cancer Research : BCR·Sarah E BurdallValerie Speirs
Sep 15, 2004·Journal of Cancer Research and Clinical Oncology·For-Wey LungFu-Hsin Chang
Mar 14, 2007·Cancer Cell·Michail ShipitsinKornelia Polyak
Oct 26, 2007·Cell Biology International·Sarangadhara Appala Raju BagadiRanju Ralhan
Sep 16, 2009·Journal of Experimental & Clinical Cancer Research : CR·Ralf Hass, Catharina Bertram
Jan 3, 2012·Proceedings of the National Academy of Sciences of the United States of America·Qiqun ZengXiyun Yan
Oct 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoko TakahashiEhab Y Hanna
Oct 19, 2014·Annals of Surgical Oncology·Maria V BogachekRonald J Weigel
Aug 18, 2016·Cancer Research·A Heather EliassenSusan E Hankinson
Jan 6, 2017·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations

Oct 2, 2021·Annals of the New York Academy of Sciences·Claire ShaoVenkata Lokesh Battula

❮ Previous
Next ❯

Methods Mentioned

BETA
scraping
flow cytometry
electrophoresis
xenograft
PCR
X-ray
xenografts

Software Mentioned

GeneMapper IDX
Prism
GraphPad

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Carcinoma, Ductal

Ductal carcinoma is a malignant neoplasm involving the ductal systems of any of a number of organs, such as the mammary glands, pancreas, prostate or lacrimal gland. Discover the latest research on ductal carcinoma here.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.